Aethlon Medical

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Aethlon Medical
Type Public
Traded as OTCQBAEMD
Genre Biotechnology
Headquarters San Diego, California, USA
Website www.aethlonmedical.com

Aethlon Medical Inc., public company based in San Diego, California and trades over-the-counter on the OTCBB under the ticker symbol "AEMD."[1][2][3] Aethlon develops medical devices to address infectious disease and cancer by filtering harmful substances from the blood, including viruses and immune-suppressing proteins.[4]

Management[edit]

James A. Joyce is the Chairman and Chief Executive Officier. Rodney S. Kenley is the President. James B. Frakes is the Chief Financial Officer. Richard H. Tullis is the Senior Vice President and Chief Science Officer.[5]

Hemopurifier[edit]

The Hemopurifier is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide. By selectively removing harmful substances from the blood, this device offers a novel methods of addressing diseases.

In design, the Hemopurifier is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier in as little as 15 minutes.

References[edit]

  1. ^ http://www.bloomberg.com/quote/AEMD:US
  2. ^ http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?ticker=AEMD
  3. ^ http://topics.nytimes.com/top/news/business/companies/aethlon-medical-inc/index.html
  4. ^ http://topics.nytimes.com/top/news/business/companies/aethlon-medical-inc/index.html
  5. ^ http://www.aethlonmedical.com/